AQX-016A is an orally active and potent SHIP1 agonist. It is a structural analog of pelorol and is three times more potent than the marine natural product pelorol at the same molar concentration. AQX-016A can activate recombinant SHIP1 enzyme in vitro and stimulate SHIP1 activity. It also inhibits the PI3K pathway and TNFa production, making it useful for various inflammatory diseases research [1] [2].

AQX-016A, across various concentrations and durations (0-15 μM, 0-90 min), demonstrably modulates immune response and signaling pathways through specific inhibition and activation mechanisms. At 5 μg/mL for 30 minutes, it suppresses the PI3K-mediated rise in intracellular PIP3 by activating a 5' phosphatase enzyme, leading to decreased PIP3 levels [1]. Furthermore, it effectively blocks LPS-induced PKB phosphorylation in a SHIP-dependent manner and significantly curtails TNFα production in J774 and peritoneal macrophages, as well as in BMDM, particularly requiring SHIP for maximum reduction of TNFα and selectively targeting TNF production from SHIP1 +/+ macrophages over SHIP1 -/- ones [1]. Additionally, AQX-016A inhibits TNFα translation and, at increased concentrations, enhances SHIP1 enzyme activity, both in vitro and in intact cells, consequently inhibiting activation of macrophages and mast cells [2]. In a dose-dependent manner, it preferentially prevents LPS-stimulated PKB phosphorylation and inhibits the phosphorylation of PKB, p38 MAPK, and ERK in SHIP1 +/+ mast cells, showcasing its specificity for SHIP-expressing hematopoietic cells, and highlights its potential in targeting PI3K-dependent responses in immune cells in a SHIP-dependent manner [2].

AQX-016A, administered orally at a dose of 20 mg/kg once, significantly lowers plasma TNFa levels and reduces inflammation in a mouse model of endotoxemia [1] [2].